- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06525298
EIS-12656 som enkeltstof og i kombination hos patienter med specificerede solide tumorer
A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor, Trastuzumab Deruxtecan (T-DXd), or Darolutamide in Patients With Specified Solid Tumors
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
The trial is a Phase 1/2, open label, uncontrolled trial to investigate the safety and preliminary efficacy of EIS-12656 alone or in combination with a PARPi, T-DXd or darolutamide in patients with specified advanced or metastatic solid tumors with homologous recombination deficient (HRD) mutations.
In the Phase 1 dose escalation phase participants will receive ascending doses of EIS-12656 to evaluate the safety and tolerability and to determine an effective and safe dose for the Phase 2 part.
In the Phase 2 dose expansion phase participants will either receive EIS-12656 monotherapy at the recommended Phase 2 dose (RP2D) (Module 1) or EIS-12656 in combination with a PARPi (Module 2), or T-DXd (Modules 3), or darolutamide (Module 4). The objective is to evaluate the safety and tolerability and anti-tumor activity of EIS-12656 alone or in combination.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Adrian Schomburg
- Telefonnummer: +49 17621046886
- E-mail: adrian@eisbach.bio
Studiesteder
-
-
Louisiana
-
Shreveport, Louisiana, Forenede Stater, 71103
- Rekruttering
- LSU Health Sciences Center- Shreveport
-
Ledende efterforsker:
- Sindhu Devarashetty, MD
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- Rekruttering
- Duke Cancer Institute
-
Ledende efterforsker:
- Rani Bansal, MD
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
Ledende efterforsker:
- Timothy Yap, MD
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98109
- Rekruttering
- Fred Hutchinson Cancer Center
-
Ledende efterforsker:
- Jennifer Specht, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Recurrent locally advanced or metastatic solid tumors
- Homologous recombination deficient mutations
- Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy
- Measurable disease (RECIST 1.1 Criteria)
- Adequate organ and bone marrow function
- ECOG Performance Status 0 or 1
- Life expectancy > 3 months
Exclusion Criteria:
- History or evidence of any clinically relevant gastrointestinal disease
- Radiation therapy within ≤2 weeks
- Significant cardiovascular disease
- Uncontrolled, active, symptomatic brain metastases
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: EIS-12656 Dosiseskalering
|
EIS-12656 tablets given daily |
|
Eksperimentel: Dosisudvidelsesmodul 1 (EIS-12656 monoterapi)
|
EIS-12656 tablets given daily |
|
Eksperimentel: Dose Expansion Module 2 (EIS-12656 + PARPi)
EIS-12656 will be given in combination with PARPi |
EIS-12656 tablets given daily as per USPI/SmPC |
|
Eksperimentel: Dose Expansion Module 3 (EIS-12656 + T-DXd)
EIS-12656 will be given in combination with Trastuzumab deruxtecan |
EIS-12656 tablets given daily as per USPI/SmPC
Andre navne:
|
|
Eksperimentel: Dose Expansion Module 4 (EIS-12656 + darolutamide + ADT)
EIS-12656 will be given in combination with darolutamide and androgen deprivation therapy (ADT) |
EIS-12656 tablets given daily as per USPI/SmPC |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number and percentage of participants experiencing treatment-emergent adverse events (TEAEs)
Tidsramme: From screening until end of treatment follow-up (45 days after last dose) (up to 7 months)
|
Number and percentage of participants with adverse events, serious adverse events, adverse events of special interest including changes in safety lab parameters, physical examinations, vital signs, and electrocardiogram (ECG) |
From screening until end of treatment follow-up (45 days after last dose) (up to 7 months)
|
|
Number and percentage of participants experiencing a dose limiting toxicity (DLT) (dose escalation part only)
Tidsramme: Within 21 days of first dose
|
A DLT is defined as an EIS-12656 related adverse event during the first treatment cycle that meets the criteria outlined in the study protocol |
Within 21 days of first dose
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum plasma concentration of EIS-12656 (Cmax)
Tidsramme: At pre-defined intervals from pre-dose Day 1 to Day 29
|
The concentration of EIS-12656 in plasma will be determined (Cmax will be derived) |
At pre-defined intervals from pre-dose Day 1 to Day 29
|
|
Area under the curve (AUC0-24)
Tidsramme: At pre-defined intervals from pre-dose Day 1 to Day 29
|
The AUC0-24 reflects the actual body exposure to drug over the last 24h dosing interval |
At pre-defined intervals from pre-dose Day 1 to Day 29
|
|
Time to maximum concentration (Tmax)
Tidsramme: At pre-defined intervals from pre-dose Day 1 to Day 29
|
The concentration of EIS-12656 in plasma will be determined (Tmax will be derived) |
At pre-defined intervals from pre-dose Day 1 to Day 29
|
|
Overall Response Rate
Tidsramme: From screening to disease progression (approximately 1 year)
|
Overall response rate defined as percentage of participants with the best overall response of confirmed CR or confirmed PR according to RECIST v1.1 |
From screening to disease progression (approximately 1 year)
|
|
Duration of Response
Tidsramme: From screening to disease progression or death (approximately 1 year)
|
Time from first response to progression or death, as defined by RECIST 1.1 |
From screening to disease progression or death (approximately 1 year)
|
|
Progression Free Survival
Tidsramme: From screening to disease progression or death (approximately 1 year)
|
Time from first dose of EIS-12656 to progression or death, as defined by RECIST 1.1 |
From screening to disease progression or death (approximately 1 year)
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- EIS-12656C01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .